Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    HomeNewsIifl capital

    Iifl Capital

    Jump to
    • IIFL Capital Consolidated September 2025 Net Sales at Rs 572.08 crore, down 11.36% Y-o-Y

      IIFL Capital Consolidated September 2025 Net Sales at Rs 572.08 crore, down 11.36% Y-o-Y

    • IIFL Capital Standalone September 2025 Net Sales at Rs 508.92 crore, down 11.31% Y-o-Y

      IIFL Capital Standalone September 2025 Net Sales at Rs 508.92 crore, down 11.31% Y-o-Y

    • IIFL Capital Consolidated June 2025 Net Sales at Rs 617.37 crore, down 3.52% Y-o-Y

      IIFL Capital Consolidated June 2025 Net Sales at Rs 617.37 crore, down 3.52% Y-o-Y

    • IIFL Capital Standalone June 2025 Net Sales at Rs 522.94 crore, down 8.4% Y-o-Y

      IIFL Capital Standalone June 2025 Net Sales at Rs 522.94 crore, down 8.4% Y-o-Y

    • IIFL Capital Consolidated March 2025 Net Sales at Rs 537.14 crore, down 21.75% Y-o-Y

      IIFL Capital Consolidated March 2025 Net Sales at Rs 537.14 crore, down 21.75% Y-o-Y

    • IIFL Capital Consolidated December 2024 Net Sales at Rs 582.59 crore, up 4.26% Y-o-Y

      IIFL Capital Consolidated December 2024 Net Sales at Rs 582.59 crore, up 4.26% Y-o-Y

    • IIFL Capital Standalone December 2024 Net Sales at Rs 516.86 crore, up 7.44% Y-o-Y

      IIFL Capital Standalone December 2024 Net Sales at Rs 516.86 crore, up 7.44% Y-o-Y

    • Dr Reddy's Lab top pick in pharma: IIFL Capital

      Dr Reddy's Lab top pick in pharma: IIFL Capital

      Bino Pathiparampil of IIFL Capital told CNBC-TV18 that there has been a major rally in the sector over the last couple of years. Thus, many of the stocks went up 20 percent in the last couple of months itself.

    • IIFL Capital underweight on cement, IT space

      IIFL Capital underweight on cement, IT space

      Deepesh Pandey, Head of Investments, IIFL Capital is underweight on cement and IT space.

    • Buy Dr Reddy's; Divis Lab, Biocon good bets: IIFL Cap

      Buy Dr Reddy's; Divis Lab, Biocon good bets: IIFL Cap

      Concentrating on the pharma space, Bino Pathiparampil of IIFL Capital told CNBC-TV18 the success of Biocon‘s oral insulin product deal would be a positive for the company. He also has a buy on Dr Reddy‘s and believes it should give a 25 percent plus upside in the next one year.

    • Deepesh Pandey overweight on private sector banks

      Deepesh Pandey overweight on private sector banks

      Deepesh Pandey, Head - Investments, IIFL Capital is overweight on private sector banks.

    • Budget Reactions: IIFL Cap neutral on Cadilla; little downside on Sun Pharma

      Budget Reactions: IIFL Cap neutral on Cadilla; little downside on Sun Pharma

      In an interview to CNBC-TV18, Bino Pathiparampil, vice president, IIFL Capital analyses the pharma sector wherein he reviews specific stocks like Sun Pharma and Cadila.

    • IIFL's prescription on how to play the pharma space

      IIFL's prescription on how to play the pharma space

      In an interview with CNBC-TV18, Bino Pathiparampil, vice president of IIFL Capital, spoke about the latest happenings in the pharma space and his call various stocks.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347